pravastatin has been researched along with B16 Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alupei, MC; Banciu, M; Cristian, FB; Licarete, E | 1 |
| Alonso, J; Cardier, JE; Ledezma, E; Wittig, O | 1 |
2 other study(ies) available for pravastatin and B16 Melanoma
| Article | Year |
|---|---|
Cytotoxicity of lipophilic statins depends on their combined actions on HIF-1α expression and redox status in B16.F10 melanoma cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoxia-Inducible Factor 1, alpha Subunit; Melanoma, Experimental; Mice; Necrosis; Oxidation-Reduction; Oxidative Stress; Pravastatin; Simvastatin | 2014 |
Potentiated cytotoxic effects of statins and ajoene in murine melanoma cells.
Topics: Animals; Apoptosis; Atorvastatin; Cell Line, Tumor; Disulfides; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Melanocytes; Melanoma, Experimental; Mevalonic Acid; Mice; Polyisoprenyl Phosphates; Pravastatin; Pyrroles; Sulfoxides; Terpenes | 2009 |